Cover Image
市場調查報告書

胃癌 - 早期階段開發平台的技術創新顯示轉移到標的單株抗體

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

出版商 GBI Research 商品編碼 357018
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
胃癌 - 早期階段開發平台的技術創新顯示轉移到標的單株抗體 Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
出版日期: 2016年03月10日 內容資訊: 英文 70 Pages
簡介

胃癌成為全球的第5大癌症。胃癌市場上,逐漸從著重化療轉向基於標靶治療的複雜治療方法。必須更深理解胃癌的病理學,並使用治療方法改善新的標的。

本報告提供胃癌的概要與目前治療方法,臨床及商業性環境,開發平台的技術創新趨勢,First-in-Class標的概要與市場上交易趨勢等彙整資料。

第1章 目錄

第2章 摘要整理

第3章 技術創新案例

第4章 臨床及商業性環境

  • 疾病概要
  • 症狀
  • 免疫學與病因
  • 病理學
  • 診斷和分期
  • 分類
  • 預後
  • 治療方法
  • 胃癌的已上市產品概要

第5章 開發中產品技術創新評估

  • 各分子類型,相位,治療標的開發平台
  • 胃癌市場與治療標的開發平台的計劃比較分佈
  • 把新分子標的作為標的First-in-Class開發平台

第6章 信號網,疾病的原因,技術創新

  • 腫瘤學的信號網的複雜性
  • 信號途徑和First-in-Class分子標的整合
  • First-in-Class矩陣評估

第7章 First-in-Class標的評估

第8章 交易與策略性整合

  • 產業的First-in-Class交易
  • 授權
  • 共同開發
  • 與授權或共同開發無關的First-in-Class計劃

第9章 附錄

圖表

目錄
Product Code: GBIHC396MR

Executive Summary

Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Scope

  • What is the pathophysiology of gastric cancer?
  • How is gastric cancer diagnosed?
  • What are the current treatment options?
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
  • What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
  • What are the most promising first-in-class targets for gastric cancer?
  • Will the current first-in-class targets have a broader therapeutic potential across the industry?
  • How do deal frequency and value compare between target families and molecule types?
  • How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
  • Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
  • Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Significant Unmet Needs in the Gastric Cancer Market
  • 2.2. High Proportion of First-in-Class Innovation Offers Promise in Gastric Cancer
  • 2.3. Deal Activity Varies with First-in-Class Status

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Development Remains Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Disease Symptoms
  • 4.3. Epidemiology and Etiology
  • 4.4. Pathophysiology
    • 4.4.1. Helicobacter Pylori
    • 4.4.2. Oncogenes
    • 4.4.3. Tumor Suppressor Genes
    • 4.4.4. Cell Adhesion Molecules and Metastasis-Related Genes
    • 4.4.5. Cell Cycle Regulators
    • 4.4.6. Microsatellite and Chromosomal Instability
    • 4.4.7. Growth Factor and Cytokines
  • 4.5. Diagnosis and Staging
  • 4.6. Classification
    • 4.6.1. Intestinal Subtype
    • 4.6.2. Diffuse Subtype
  • 4.7. Prognosis
  • 4.8. Treatment Options
    • 4.8.1. Surgery
    • 4.8.2. First-Line Therapy
    • 4.8.3. Second-Line Therapy
  • 4.9. Overview of Marketed Products in Gastric Cancer
    • 4.9.1. Molecule Type and Target Analysis
    • 4.9.2. Innovative Products in Gastric Cancer Market
    • 4.9.3. Unmet Needs

5. Assessment of Pipeline Product Innovation

  • 5.1. Gastric Cancer Pipeline by Molecule Type, Phase and Therapeutic Target
  • 5.2. Comparative Distribution of Programs between the Gastric Cancer Market and Pipeline by Therapeutic Target Family
  • 5.3. First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6. Signaling Network, Disease Causation and Innovation Alignment

  • 6.1. Complexity of Signaling Networks in Oncology
  • 6.2. Signaling Pathways and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting HER 3
  • 7.2. Pipeline Programs Targeting Ataxia Telangiectasia Mutated
  • 7.3. Pipeline Programs Targeting L1 Cell Adhesion Molecule
  • 7.4. Pipeline Programs Targeting Akt 1, 2 and 3
  • 7.5. Pipeline Programs Targeting Fibroblast Growth Factor receptor 3
  • 7.6. Pipeline Programs Targeting 3-Phosphoinositide-Dependent Protein Kinase 1
  • 7.7. Conclusion

8. Deals and Strategic Consolidation

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
    • 8.2.1. Licensing Deals by Molecule Type
    • 8.2.2. Licensing Deals by Molecular Target
    • 8.2.3. Conclusion
  • 8.3. Co-development Deals
    • 8.3.1. Co-development Deals by Molecule Type
    • 8.3.2. Co-development Deals by Molecular Target
    • 8.3.3. Conclusion
  • 8.4. First-in-Class Programs Not Involved in Licensing or Co-development Deals

9. Appendix

  • 9.1. References
  • 9.2. Abbreviations
  • 9.3. Research Methodology
  • 9.4. Secondary Research
    • 9.4.1. Marketed Product Heatmaps and Treatment Algorithm
    • 9.4.2. Pipeline Analysis
    • 9.4.3. First-in-Class Matrix Assessment
    • 9.4.4. First-in-Class Target Profiles
    • 9.4.5. Licensing and Co-Development Deals
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging
  • Table 2: Gastric Cancer, Key Features and Pipeline Activity of HER 3
  • Table 3: Gastric Cancer, Key Features and Pipeline Activity of ATM
  • Table 4: Gastric Cancer, Key Features and Pipeline Activity of L1CAM
  • Table 5: Frequency of Mutations in Components in Akt Proteins, by Cancer Type
  • Table 6: Gastric Cancer, Key Features and Pipeline Activity of AKT 1
  • Table 7: Gastric Cancer, Key Features and Pipeline Activity of AKT 2
  • Table 8: Gastric Cancer, Key Features and Pipeline Activity of AKT 3
  • Table 9: Gastric Cancer, Key Features and Pipeline Activity of FGFR-3
  • Table 10: Gastric Cancer, Key Features and Pipeline Activity of PDPK1
  • Table 11: List of Abbreviations

List of Figures

  • Figure 1: Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2012
  • Figure 2: First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval ($m)
  • Figure 3: Gastric Cancer, Heatmap for First-Line Marketed Products
  • Figure 4: Gastric Cancer, Heatmap for Second-Line Therapy Marketed Products
  • Figure 5: Gastric Cancer, Overview of Marketed Products
  • Figure 6: Gastric Cancer , Overview of Pipeline Products
  • Figure 7: Gastric Cancer, Molecular Targets in Pipeline
  • Figure 8: Gastric Cancer, Pipeline by Molecular Targets and Stage of Development
  • Figure 9: Gastric Cancer, Molecular Target Family Comparison, Pipeline and Marketed Products
  • Figure 10: Gastric Cancer, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets
  • Figure 11: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%)
  • Figure 12: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Stage of Development (%)
  • Figure 13: Gastric Cancer, First-in-Class Products in Pipeline (Part 1)
  • Figure 14: Gastric Cancer, First-in-Class Products in Pipeline (Part 2)
  • Figure 15: Gastric Cancer, First-in-Class Products in Pipeline (Part 3)
  • Figure 16: Gastric Cancer, Target Matrix Assessment (Part 1)
  • Figure 17: Gastric Cancer, Target Matrix Assessment (Part 2)
  • Figure 18: Gastric Cancer, Programs Targeting HER 3
  • Figure 19: Gastric Cancer, Programs Targeting ATM
  • Figure 20: Gastric Cancer, Programs Targeting L1CAM
  • Figure 21: Gastric Cancer, Programs Targeting AKT 1
  • Figure 22: Gastric Cancer, Programs Targeting AKT 2
  • Figure 23: Gastric Cancer, Programs Targeting AKT 3
  • Figure 24: Gastric Cancer, Programs Targeting FGFR 3
  • Figure 25: Gastric Cancer, Programs Targeting PDPK1
  • Figure 26: Gastric Cancer, Deals by Stage of Development, 2006-2014
  • Figure 27: Gastric Cancer, Licensing Deal Values by Stage of Development ($m), 2006-2014
  • Figure 28: Gastric Cancer, Licensing Deal Value, 2006-2015
  • Figure 29:Gastric Cancer, Licensing Deals by Year, 2006-2015
  • Figure 30: Gastric Cancer, Licensing Deals by Stage of Development, 2006-2015
  • Figure 31: Gastric Cancer, Licensing Deal Value by Stage of Development and Molecule Type, 2006-2015
  • Figure 32: Gastric Cancer, Licensing Deal Value by Molecular Target, 2006-2015
  • Figure 33: Gastric Cancer, Summary of Licensing Deals, 2006-2015
  • Figure 34: Gastric Cancer, Co-development Deal Value, 2006-2015
  • Figure 35: Gastric Cancer, Co-development Deals by Year, 2006-2015
  • Figure 36: Gastric Cancer, Co-development Deals by Stage of Development, 2006-2015
  • Figure 37: Gastric Cancer, Co-development by Stage of Development and Molecule Type, 2006-2015
  • Figure 38: Gastric Cancer, Co-development by Stage of Development and Molecular Target, 2006-2015
  • Figure 39: Gastric Cancer, Summary of Co-development Deals, 2006-2015
  • Figure 40: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 1)
  • Figure 41: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 2)
Back to Top